41324-79-2

Usage

Uses

Used in Biochemical Research:
L-Alanine, cyclohexyl ester, hydrochloride is used as a research compound for its potential biological activities, particularly in the study of amino acids and their derivatives.
Used in Pharmaceutical Applications:
L-Alanine, cyclohexyl ester, hydrochloride is used as an intermediate in organic synthesis for the development of pharmaceutical products, leveraging its unique properties and reactivity in chemical reactions.
Used in Chemical Synthesis:
L-Alanine, cyclohexyl ester, hydrochloride is used as a reagent in chemical synthesis processes, taking advantage of its ester functionality and compatibility with various reaction conditions.
Used in Analytical Chemistry:
L-Alanine, cyclohexyl ester, hydrochloride is used as a standard or reference material in analytical chemistry for the calibration of instruments and the development of analytical methods.
Used in Nutritional Supplements:
L-Alanine, cyclohexyl ester, hydrochloride may be used as a component in nutritional supplements, contributing to the amino acid profile and supporting various physiological functions.
Used in Cosmetics and Personal Care Products:
L-Alanine, cyclohexyl ester, hydrochloride may be used in cosmetics and personal care products for its potential benefits in skin health and conditioning, although its use in this industry may be limited due to its potential for irritation.

Upstream product

• 56-41-7 L-alanin 
• 108-93-0 cyclohexanol 

Downstream Products

• 220592-67-6 O-phenyl-N-(S)-1-(cyclohexoxycarbonyl)ethylphosphoramidic chloride 
• 1439900-33-0 (2S)-2-(((perfluorophenoxy)(phenoxy)phosphoryl)amino)propionic acid cyclohexyl ester 
• 1371631-75-2 2'-deoxy-2',2'-difluoro-D-cytidine-5'-O-bis(cyclohexoxy-L-alaninyl)-phosphate 
• 1234489-08-7 (2S)-cyclohexyl 2-((chloro(naphthalen-1-yloxy)phosphoryl)amino)propanoate 
• 1445380-43-7 C₂₉H₄₇FN₅O₉P 
• 912338-14-8 methyl (2S)-2-[(2S)-2-{[(tert-butoxy)carbonyl](methyl)amino}propanamido]-2-cyclohexylacetate 
• 1350765-94-4 (2S,2'S)-dicyclohexyl 2,2'-((((2R,3R,4R,5R)-5-(2-amino-6-ethoxy-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)phosphoryl)bis(azanediyl)dipropanoate 
• 1350765-20-6 (25,2'5)-dicyclohexyl-((((2R,35,4R,5R)-5-(2-amino-6-methoxy-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy) phosphoryl)-(2,2')-bis-amino-dipropanoate 

Relevant academic research and scientific papers

ANTIVIRAL COMPOUNDS

The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, Ebola, Zika, West Nile, Dengue, and HCV.

PRODRUGS OF 4'-C-SUBSTITUTED-2-HALO-2'-DEOXYADENOSINE NUCLEOSIDES AND METHODS OF MAKING AND USING THE SAME

The present disclosure provides prodrugs of 4'-C-substituted-2- halo-2'-deoxyadenoside nucleosides, and compositions, methods and kits thereof. Such compounds can be useful for treating viral infections including, human immunodeficiency virus. The compounds have the following formula (I).

ANTIVIRAL COMPOUNDS

The present disclosure describes 4'-fluoromethyl nucleosides for treating viral infections, including Dengue.

ANTIVIRAL COMPOUNDS

The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, ebola, Zika, West Nile, Dengue, and HCV.

A 5-(4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZIN-7-YL)-2-CYANO-3,4-DIHYDROXYTETRAHYDROFURANE DERIVATIVE AS ANTIVIRAL AGENT

The present disclosure provides a compound of Formula (I) which is useful in treating a variety of diseases, such as diseases caused by respiratory syncytial virus (RSV), HRV, hMPV, ebola, Zika, West Nile, Dengue, HCV and/or HBV infections.

Discovery of 2'-α-C-Methyl-2'-β-C-fluorouridine Phosphoramidate Prodrugs as Inhibitors of Hepatitis C Virus

2′-α-C-Methyl-2′-β-C-fluorouridine and its phosphoramidate prodrugs were synthesized and evaluated for their inhibitory activity against HCV. The structure?activity relationship analysis of the phosphoramidate moiety found that 17m, 17q, and 17r exhibit potent activities against HCV, with EC50 values of 1.82 ± 0.19, 0.88 ± 0.12, and 2.24 ± 0.22 μM, respectively. The docking study revealed that the recognition of the 2′-β-F by Arg158, 3′-OH by N291, and the Watson?Crick pairing with the template allowed 23 to form the in-line conformation necessary for its incorporation into the viral RNA chain.

Cyclic phosphoramidates as prodrugs of 2′-C-methylcytidine

The currently approved treatment for hepatitis C virus infections is a combination of Ribavirin and pegylated Interferon. It leads to a sustained virologic response in approximately only half of the patients treated. For this reason there is an urgent need of new therapeutic agents. 2′-C-Methylcytidine is the first nucleoside inhibitor of the HCV NS5B polymerase that was efficacious in reducing the viral load in patients infected with HCV. The application of a monophosphate prodrug approach based on unprecedented cyclic phosphoramidates is reported. Our SAR studies led to compounds that are efficiently converted to the active triphosphate in human hepatocytes.